Aprofol is a Swiss life science company, currently in the development phase. Aprofol specialises in folates, the nature-identical derivatives of folic acid, and brings many years of experience together with the most recent findings in the fields of medicine, biology and pharmacology.

Since the company was founded in April 2013 focusing on folates has resulted in two patent applications. In the USA the patents were granted in 2016 and 2017 respectively. In Europe, Japan and other countries the patents are still pending. Innovative products are developed for established as well as new uses with Aprofol technology.

Folate intake through food consumption is too low in many populations. Taking food supplements can compensate deficiencies or can supplement an increased need (e.g. during pregnancy). High-dosage folate products are mainly used to treat chronic diseases. These products are classified as medicines.

We are convinced that deficiencies often cause chronic diseases and severely impair quality of life. If such deficiencies are left untreated, the symptoms can seldom be prevented, alleviated or cured.

Aprofol develops and markets products which contain folate both as a dietary supplement and a medication..